BCR-ABL activity and its response to drugs can be determined in CD34+ CML stem cells by CrkL phosphorylation status using flow cytometry
Open Access
- 30 March 2006
- journal article
- research article
- Published by Springer Science and Business Media LLC in Leukemia
- Vol. 20 (6), 1035-1039
- https://doi.org/10.1038/sj.leu.2404189
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CMLBlood, 2005
- Punish the parent not the progenyBlood, 2005
- Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitroBlood, 2002
- Roots of Clinical Resistance to STI-571 Cancer TherapyScience, 2001
- Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in vitro in association with up-regulation of expression of interleukin-3Blood, 2001
- The molecular biology of chronic myeloid leukemiaBlood, 2000
- Isolation of a Highly Quiescent Subpopulation of Primitive Leukemic Cells in Chronic Myeloid LeukemiaBlood, 1999
- Identification of CRKL as the constitutively phosphorylated 39-kD tyrosine phosphoprotein in chronic myelogenous leukemia cellsBlood, 1994
- Tyrosine phosphorylation of CRKL in Philadelphia+ leukemiaBlood, 1994
- A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia identified by Quinacrine Fluorescence and Giemsa StainingNature, 1973